Boehringer Ingelheim has announced a partnership with Autifony Therapeutics that aims to create new advances in the treatment of central nervous system disorders.
Boehringer Ingelheim now has an exclusive option to purchase Autifony’s Kv3.1/3.2 voltage-gated potassium channel modulator platform, including the lead compound AUT00206, which is being assessed in phase Ib studies for conditions such as schizophrenia.
“Boehringer Ingelheim is partnering with Autifony Therapeutics on the development of new therapies for central nervous system disorders.“
Under the terms of the deal, Boehringer Ingelheim will pay Autifony a 25 million euro (22.07 million pounds) upfront fee, with further payments of up to 17.5 million euros contingent on achievement of short-term milestones. The total potential transaction may be worth up to 627.5 million euros if all intended goals are met.
Schizophrenia is the most advanced indication under development with AUT00206, with preclinical studies indicating that the compound has the potential to treat cognitive and negative symptoms of the condition, with fewer side effects than current therapies.
Dr Charles Large, chief executive officer of Autifony Therapeutics, said: "We welcome the opportunity to collaborate with Boehringer Ingelheim, who will bring valuable expertise and resources as we progress through the next phases of clinical and non-clinical development."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical